•   
  •   

Health & Fitness Moderna's covid vaccine may NOT block covid-positive from spreading it

23:05  24 november  2020
23:05  24 november  2020 Source:   dailymail.co.uk

When should we start testing COVID-19 vaccines in kids?

  When should we start testing COVID-19 vaccines in kids? A vaccine cannot be approved for use in kids until vaccine trials with young participants are complete. Bacteria and viruses that are deadly to one type of creature can evolve quickly to infect another. While the new coronavirus SARS-CoV-2 (which causes COVID-19) is the latest example, a host of infectious and deadly diseases have hopped from animals to humans and even from humans to animals.

Moderna Inc. said its Covid -19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage Fast-paced hunt for prevention is paying off with new tools. Interim results suggest vaccine may The vaccine also appeared to be effective in preventing the most serious Covid -19 infections.

About mRNA-1273, Moderna 's Vaccine Candidate Against COVID -19. Moderna currently has 9 development candidates in its prophylactic vaccines modality. To date, Moderna has demonstrated positive Phase 1 data readouts for 6 prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus

a close up of a bottle: MailOnline logo © Provided by Daily Mail MailOnline logo

Moderna's vaccine may not prevent people who catch coronavirus from spreading it to others, the firm's chief scientist has admitted.

But Tal Zaks added that he does 'believe' the shot will do so - trials just haven't tested that yet in a recent https Axios interview.

He urged Americans not to 'over-interpret' the vaccine's promising trial results, which showed it is 94.5 percent effective at preventing people from getting sick from coronavirus.

Neither Pfizer nor Moderna used methods in their vaccine trials that allow them say for sure if their shots prevent transmission.

Exeter coronavirus vaccine: BGC is given to 1,000 people in trial

  Exeter coronavirus vaccine: BGC is given to 1,000 people in trial The Bacillus Calmette-Guérin (BCG) vaccine will be enrolled to 1,000 people by the University of Exeter after the shot was found to stimulate the immune system. It would not be the ultimate solution, but would instead help people fight off coronavirus until more effective vaccines are discovered.Prof John Campbell, at the University of Exeter Medical School, told the Guardian the vaccine could be a 'global game-changer'.

Moderna ’s vaccine is among several front-runners that have emerged from the more than 100 coronavirus vaccines in development world-wide. The early data suggest Moderna ’s vaccine , code-named mRNA-1273, “has a very good chance to provide protection” from Covid -19, the disease

A Covid -19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.

Although its trials are still ongoing, early data released Monday by AstraZeneca suggests that the vaccine it developed with Oxford University might in fact prevent viral spread.

a close up of a bottle: Moderna knows its vaccine can prevent illness from coronavirus, but its trials did not reveal whether the shot stops people from becoming asymptomatic spreaders © Provided by Daily Mail Moderna knows its vaccine can prevent illness from coronavirus, but its trials did not reveal whether the shot stops people from becoming asymptomatic spreaders

'Our results show that this vaccine can prevent you from being sick, it can prevent you from being severely sick,' Zaks told Axios.

'They do not show that this vaccine can prevent you from potentially transiently carrying the virus transiently and infecting others.'

Like most vaccines, Moderna's does not kill the virus if you inhale it, so the shot itself is not eliminating the virus.

Coronavirus vaccine trials will not tell us if a jab saves lives, expert stresses

  Coronavirus vaccine trials will not tell us if a jab saves lives, expert stresses Ongoing coronavirus vaccine trials cannot prove a jab could save lives, one expert has stressed. An effective immunisation programme has long been hailed as a route back to life as we knew it. Hopes were raised in July when scientists from the University of Oxford found a vaccine candidate induced “strong antibody and T-cell immune responses up to day 56 of the ongoing trial”. Antibodies and T-cells make up part of the immune system, helping to prevent an infection from taking hold.Russia’s controversial vaccine candidate also brought about an immune response within 21 days, however, some experts later called the results “highly unlikely”.

Volunteers who received Moderna 's Covid -19 vaccine had positive early results Moderna has vaccinated dozens of study participants and measured antibodies in eight of them. "We've demonstrated that these antibodies, this immune response, can actually block the virus," Zaks said.

The vaccine also produced neutralizing antibodies against Covid -19 in at least eight participants, the company said. Moderna , which has been fast-tracking work with the National Institutes of Health to develop a vaccine , is the first company to release data on a human trial testing a coronavirus vaccine .

Instead, it is designed with the intent of preventing the virus from latching onto receptors on human cells that let the virus weasel its way into those cells.

Viruses exist in a weird sort of purgatory between being living and non-living things. Unlike more complicated human cells, viruses can't make their own energy.

Instead, they have to hijack the machinery of human or animal cells, pirating that energy and allowing the virus to make copies of itself.

Without getting into our cells and taking them over for its own purposes, the virus can't replicate.

And a lower viral load generally means that the virus is less likely to be potent enough to infect someone else.

But Moderna hasn't proven that.

According to Science Magazine, Pfizer and Moderna only tested trial members who developed potential symptoms of COVID-19 symptoms for the virus.

Without knowing of others members of the trials might have been asymptomatic spreaders, there was no way to say for sure whether the vaccine prevented them from infecting others.

Only a 'small chance' of a Covid-19 vaccine by Xmas: Oxford

  Only a 'small chance' of a Covid-19 vaccine by Xmas: Oxford Oxford University's Professor Andrew Pollard poured cold water on the idea a vaccine could be rolled out by the end of the year. As did Kate Bingham, the UK's vaccine tsar.Professor Andrew Pollard said he was optimistic data showing his team's vaccine works and is safe will be available by the end of the year.

Moderna says Covid 19 vaccine shows promise in early trials, excites markets - TV9 - Продолжительность: 3:53 TV9 USA 362 172 просмотра.

Study subjects who received Moderna 's COVID -19 vaccine had positive early results, according to the biotech company, which partnered with the National Institutes of Health to develop the vaccine . Published Monday, May 18, 2020 11:01AM EDT Last Updated Monday, May 18, 2020 1:18PM EDT.

'When we start the deployment of this vaccine we will not have sufficient concrete data to prove that this vaccine reduces transmission,' Zaks said.

'Do I believe that it prevents transmission? Absolutely, yes, but I saw this because of the science.

'But absent proof I think it's important we don't change behaviors solely on the basis of vaccination,' Zaks added, suggesting that Americans continue to use non-medical methods like mask wearing and social distancing to stem the spread of coronavirus.

Moderna will continue to collect data if and when its shot gets emergency authorization. This additional data may tell the company if its shot can prevent the virus from spreading.

Oxford University and AstraZeneca had all trial participants swab themselves at home, allowing it to test whether the vaccine was preventing people from having transmissible coronavirus, or just preventing the virus from making them sick.

Its trials are ongoing, but the company said Monday that data looks promising that the shot may prevent spread.

Read more

Half-dose of Oxford vaccine was NOT a 'mistake', scientists say .
Oxford University's researchers have insisted they knew about the different dosing regimens and agreed everything with regulators before people were given the injectionsIn a hit back against claims that the team had accidentally given people the wrong doses of the vaccine, the researchers said they had known the doses would be smaller because of a manufacturing issue before they injected them.

usr: 1
This is interesting!